Clinical Trials

Inclusion Criteria:

• Aged 60 and over AND identified as being at high risk for PDAC at the discretion of the PI or by at least one of the following criteria:
  • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis;
  • 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family;
  • BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family;
  • Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+;
  • Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+;
  • Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+.

Exclusion Criteria:

• Under the age of 60.
• Pregnancy (to be confirmed by the patient, no pregnancy test is needed.
• Inclusion/exclusion age increased to 60 as most high risk PDAC patients are older).
• Individuals with pacemakers.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/26/23. Questions regarding updates should be directed to the study team contact.